<i>KRAS</i> Mutations Impact Clinical Outcome in Metastatic Non-Small Cell Lung Cancer

There is an urgent need to identify new predictive biomarkers for treatment response to both platinum doublet chemotherapy (PT) and immune checkpoint blockade (ICB). Here, we evaluated whether treatment outcome could be affected by <i>KRAS</i> mutational status in patients with metastati...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ella A. Eklund, Clotilde Wiel, Henrik Fagman, Levent M. Akyürek, Sukanya Raghavan, Jan Nyman, Andreas Hallqvist, Volkan I. Sayin
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI AG 2022-04-01
Colecção:Cancers
Assuntos:
lung cancer
<i>KRAS</i>
chemotherapy
immunotherapy
biomarker
Acesso em linha:https://www.mdpi.com/2072-6694/14/9/2063
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados